When your liver suddenly fails on top of long-term liver disease, the next month can be life or death. A new meta-analysis of 1,958 patients with acute-on-chronic liver failure (ACLF) found that a treatment called nonbioartificial liver support (NBALS) reduced the risk of dying within 28 days by 28% compared with standard medical therapy alone. The benefit was strongest in people whose disease severity fell in the middle range, with a MELD score between 25 and 30. Those with very high MELD scores above 30 also saw a survival benefit. But for patients with milder disease (MELD under 25), the picture was murky: the numbers pointed toward a benefit, but the range was so wide that researchers could not be confident. The analysis also found that NBALS led to a larger drop in total bilirubin, a marker of liver function. The study did not report safety data, so it is unclear how well patients tolerated the treatment or whether side effects occurred. The findings suggest that timing matters: giving NBALS to the right patients at the right stage of illness may be key. More research is needed to confirm these results and to understand who benefits most.
Nonbioartificial liver support reduces 28-day mortality in acute-on-chronic liver failure by 28% compared to standard therapyLiver Support Device Cuts 28-Day Death Risk in Sickest Patients
AI-generated summary of the cited source, checked by automated accuracy review. How we work
This meta-analysis evaluated the efficacy of nonbioartificial liver support (NBALS) compared to standard medical therapy (SMT) in 1958 patients with acute-on-chronic liver failure (ACLF). The primary finding was that NBALS significantly reduced 28-day mortality compared with SMT (RR 0.72; 95% CI [0.63-0.83]). Additionally, the NBALS group achieved a significantly higher reduction in total bilirubin compared to SMT (MD 98.15; 95% CI [66.50-129.79]).
Subgroup analyses by MELD scores revealed varying levels of certainty. Patients in the intermediate MELD group (25-30) showed a survival benefit (RR 0.65; 95% CI [0.52-0.81]), and those in the high MELD group (>30) also showed a survival benefit (RR 0.75; 95% CI [0.58-0.98]). However, there was substantial uncertainty regarding the survival benefit in the low MELD group (<25) due to high heterogeneity (I=67.9%).
The authors note that early stratification based on disease severity is crucial for optimizing NBALS application, as the maximum survival benefit was concentrated in the MELD range of 25-32. These findings suggest that while NBALS is effective, its clinical utility may be most predictable in patients with higher severity scores.
How this fits prior evidence
This meta-analysis addresses a gap in identifying effective interventions for acute-on-chronic liver failure. It extends the clinical context by providing a quantified mortality reduction for nonbioartificial liver support. While previous evidence noted that immune-modulating therapies for sepsis in liver disease lack robust clinical evidence and thymosin alpha1 showed potential in HBV-ACLF, this study provides a specific quantitative reduction in 28-day mortality (RR 0.72) for NBALS. It also provides more granular data on how MELD scores correlate with survival benefits compared to the prognostic models previously discussed.
Common questions
What is nonbioartificial liver support?
Nonbioartificial liver support (NBALS) is a treatment that helps filter toxins from the blood when the liver is failing. It does not use living liver cells. In this meta-analysis, NBALS was compared with standard medical therapy alone in patients with acute-on-chronic liver failure.
Who benefits most from this treatment?
The study found the strongest survival benefit in patients with intermediate disease severity, with a MELD score between 25 and 30. Those with high MELD scores above 30 also benefited. For patients with low MELD scores under 25, the benefit was uncertain. Talk to your doctor about your MELD score and whether this treatment might help you.
How much does it reduce the risk of dying?
The meta-analysis found that NBALS reduced the risk of dying within 28 days by 28% compared with standard medical therapy. The result was statistically significant, with a risk ratio of 0.72. However, individual results may vary, and the study did not report absolute numbers.
What are the side effects of nonbioartificial liver support?
The study did not report any safety data, including side effects, serious adverse events, or how well patients tolerated the treatment. That means we do not know from this analysis what risks might be involved. If you are considering this treatment, ask your doctor about potential side effects and whether it is appropriate for you.
More on Acute-on-chronic liver failure
View Original Abstract ↓
Higher TyG Index Linked to 4.36-Fold Increased Odds of NAFLD in Large Meta-Analysis
TyG Index Linked to Higher Fatty Liver Risk
Related in Gastroenterology
From Other Specialties
